Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Abivax [ABVX] ::.

Abivax is a biopharmaceutical company, specializing in the development of antiviral drugs and vaccines against infectious diseases. Its lead products ABX464, is currently under clinical development for HIV patients.

The coverage was initiated Aug 31st, 2017

Our target price for Abivax as of May 31th, 2018, is €16/ share

From Feb 12th, 2018, Aurgalys analyst reports on Abivax will be published in English and French

A partir du 12 février 2018, les rapports d’analyse d’Aurgalys sur Abivax seront publiés en Français et en Anglais